81% Of Proriasis Patients Benefited From AIN457 In Phase II legal proceeding Medical News Today At the annual European lyceum of Dermatology and Venereology (EADV) Congress in Lisbon, Portugal, Novartis announced affirmative results from its iii Phase II trials of AIN457 (secukinumab), a drug designed for the attention of psoriasis . ... Link To Article
No comments:
Post a Comment